CarboCode Germany GmbH
The company, based in Constance has set itself the goal of developing a novel glycosphingolipid product family that can be used in the control and prevention of age-related cognitive decline as well as neurodegenerative diseases such as Alzheimer’s, Parkinson’s disease and Huntington’s disease.
In developing the novel glycosphingolipid family, the young company uses high-performance synthesis technologies for carbohydrate and lipid chemistry as well as for in vivo and in vitro biotechnology.
CarboCode Germany GmbH employs an international team of five researchers at their office in Constance.